TNFSF10 and glioma: Other cell types, including MeWo melanoma cells, MDA breast cancer cells, and primary GBM cells, had very little or only moderate response to GFP‐TRAIL treatment (Figure 4), with only 13 ± 5%, 43 ± 3%, and 31 ± 1% cell death, respectively, while U87 human glioma cells showed no significant TRAIL‐mediated killing (2 ± 3% cell death).